Characterization of a DRD2 Variant that is Associated With a Movement Disorder

与运动障碍相关的 DRD2 变体的特征

• 批准号: 10029640
• 负责人: KIM Arthur NEVE
• 金额: $ 34.5万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10029640
• 关键词: Affect; Agonist; Animal Model; Arrestins; Behavior; Binding; Biological; Brain; Calmodulin; Cell Line; Cell surface; Cells; Characteristics; Chorea; Clinical; Crystallization; Cyclic AMP; DRD2 gene; Data; Disease; Dopamine; Dopamine D2 Receptor; Dopamine Receptor; Dyskinetic syndrome; Dystonia; Electrophysiology (science); Embryo; Evaluation; Exhibits; Exons; Family; Functional disorder; G-Protein-Coupled Receptors; GTP-Binding Proteins; Generations; Genes; Genetic; Genetic Polymorphism; Goals; Government; Human; Huntington gene; Impairment; Investigation; Kidney; Kinetics; Knock-in Mouse; Laboratories; Link; Lipid Bilayers; Mental disorders; Midbrain structure; Modeling; Motor; Movement Disorders; Mus; Mutate; Neostriatum; Neurologic Dysfunctions; Neurologic Symptoms; Neurons; Parkinson Disease; Pathogenicity; Persons; Phenotype; Property; RIPK1 gene; Receptor Signaling; Research; Schizophrenia; Signal Transduction; Single Nucleotide Polymorphism; Slice; Structure; Substance abuse problem; System; Testing; Therapeutic; Variant; Work; desensitization; dopamine system; dopaminergic neuron; genetic pedigree; genetic variant; in vivo; member; motor impairment; mouse model; mutant; nervous system disorder; novel; protein activation; protein expression; receptor; receptor binding; receptor expression; receptor function; recruit; societal costs; therapeutic target

Project Summary Dopamine receptors are the primary therapeutic targets for a variety of neurological and psychiatric disorders, including schizophrenia, Parkinson's disease, and many other movement disorders. The five subtypes of dopamine receptors (D1-D5) are members of the superfamily of G protein-coupled receptors. This proposal is focused on the D2 receptor and, in particular, on the functional consequences of a novel DRD2 allelic variant that is linked to a movement disorder in at least one pedigree. The two Aims will test the hypotheses that the putatively pathogenic variant will exhibit altered signaling and cell surface expression compared to the reference D2 receptor when expressed in a neuronal cell line (Aim 1) or in dopamine neurons in mouse brain (Aim 2a), and that mice expressing the novel variant will exhibit motor impairments consistent with the human phenotype (Aim 2b). In Aim 1 we will determine if the impaired recruitment of arrestin and enhanced activation of G proteins observed when expressed in human embryonic kidney 293 cells is also characteristic of the novel variant when expressed in a neuronal cell line. In Aim 2 we will create a knock-in mouse model of homozygous and heterozygous expression of the putatively pathogenic variant. We will evaluate the functional properties of the novel variant in midbrain dopamine neurons using slice electrophysiology, and conduct analyses of behaviors that are thought to model the human clinical condition. In addition, D2 receptor expression will be quantified in midbrain and neostriatum of the knock-in mouse. The aims proposed here will quantify the effect of this novel polymorphism on the function and expression of the D2 receptor in neuronal cells and in mouse brain and should provide a biological explanation for manifestation of neurological dysfunction in humans with this variant.

项目摘要 多巴胺受体是各种神经和精神疾病的主要治疗靶点， 包括精神分裂症、帕金森氏症和许多其他运动障碍。的五个子类型 多巴胺受体(D1-D5)是G蛋白偶联受体超家族的成员。这项建议是 重点是D2受体，特别是一种新的DRD2等位基因变体的功能后果 这与至少一个家系中的运动障碍有关。这两个目标将检验以下假设： 与可能致病的变异体相比，其信号和细胞表面的表达会发生改变 参考D2受体在神经细胞系(Aim 1)或小鼠脑内多巴胺神经元中表达 (目标2a)，并且表达新变体的小鼠将表现出与人类一致的运动障碍 表型(目标2b)。在目标1中，我们将确定Arrestin的招募受损和激活增强 在人类胚胎肾脏293细胞中观察到的G蛋白的表达也是新的特征 在神经细胞系中表达时的变异。在目标2中，我们将创建纯合子敲入小鼠模型 以及疑似致病变异体的杂合表达。我们将评估的功能属性 中脑多巴胺神经元的新变种的切片电生理学，并进行了分析 被认为是模拟人类临床状况的行为。此外，D2受体的表达将 在敲入小鼠的中脑和新纹状体中定量。这里提出的目标将量化影响 D2受体在神经细胞和小鼠中的功能和表达 并应为人类神经功能障碍的表现提供生物学解释 这个变种。

项目成果

Reply to: "Childhood Onset Chorea Caused by a Recurrent De Novo DRD2 Variant".

回复：“由复发性新发 DRD2 变异引起的儿童期舞蹈病”。

• DOI: 10.1002/mds.28635
• 发表时间: 2021
• 期刊: Movement disorders : official journal of the Movement Disorder Society
• 作者: vanderWeijden,MarlousCM;Rodriguez-Contreras,Dayana;Neve,KimA;Verbeek,DinekeS;Tijssen,MarinaAJ
• 通讯作者: Tijssen,MarinaAJ

A Gain-of-Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype.

• DOI: 10.1002/mds.28385
• 发表时间: 2021-03
• 期刊: Movement disorders : official journal of the Movement Disorder Society
• 作者: van der Weijden MCM;Rodriguez-Contreras D;Delnooz CCS;Robinson BG;Condon AF;Kielhold ML;Stormezand GN;Ma KY;Dufke C;Williams JT;Neve KA;Tijssen MAJ;Verbeek DS
• 通讯作者: Verbeek DS